Quality of life after Uphold (TM) Vaginal Support System surgery for apical pelvic organ prolapse-A prospective multicenter study

Rahkola-Soisalo, Paivi

2017-01


http://hdl.handle.net/10138/233265
https://doi.org/10.1016/j.ejogrb.2016.11.011

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
Full length article

Quality of life after Uphold™ Vaginal Support System surgery for apical pelvic organ prolapse—A prospective multicenter study

Päivi Rahkola-Soisalo a,*, Daniel Altman b,c, Christian Falconer c, Edward Morcos c, Martin Rudnicki d, Tomi S. Mikkola a,e

a University of Helsinki and Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Finland
b Stockholm Urological Clinical, Sweden
c Division of Obstetrics and Gynecology, Karolinska Institutet Danderyd Hospital, Sweden
d Odense University Hospital, Department of Obstetrics and Gynecology, Denmark
e Finsbylak Research Center, Helsinki, Finland

A R T I C L E   I N F O

Article history:
Received 13 May 2016
Received in revised form 4 October 2016
Accepted 13 November 2016

Keywords:
Quality of life
Pelvic organ prolapse
Cystocele
Uterine prolapse
Transvaginal mesh

A B S T R A C T

Objective: To study the effects on quality of life in women operated for apical pelvic organ prolapse using the Vaginal Uphold™ System.

Study design: In this prospective cohort study, women (n = 207) with symptomatic apical prolapse, with or without cystocele, were operated using the Uphold™ Vaginal Support System. Follow-up for quality of life was performed at 12 months after surgery, and assessed by the PFDI-20, and PFIQ-7, and sexual function by the PISQ-12. We used odds ratios (ORs) with 95% confidence intervals (CIs) for outcome association analyses using logistic regression.

Results: At one-year follow-up majority of women experienced an overall postoperative improvement in quality of life (p < 0.001). One year after surgery Uphold™ operation alone increased the risk for prolapse related bother as compared to Uphold™ combined with anterior colporraphy (POP-IQ-7; OR 2.1; 95% CI 1.01–4.3). The frequency of dyspareunia decreased postoperatively (p = 0.004), however, after one-year, overall sexual function deteriorated significantly (p < 0.001). The worsening in sexual function scores was mainly attributed to the partner related domain, whereas the behavioral-emotive and physical domains showed no significant changes.

Conclusion: Apical prolapse repair using Uphold™ improved quality of life among our patients but worsened overall sexual function postoperatively.

© 2016 Elsevier Ireland Ltd. All rights reserved.

Introduction

Although the restoration of vaginal topography often results in improvements in pelvic organ prolapse symptoms the incongruence between objective and subjective outcomes in pelvic organ prolapse surgery is well established [1–3]. As a consequence, the focus of pelvic organ prolapse surgery has pivoted towards patients centered outcomes and quality of life measures, [4–6] rather than simply measuring pelvic anatomy outcomes of surgery.

In women after pelvic organ prolapse surgery quality of life measures may entail a variety of domains of which the effects on sexual function has received perhaps the most attention [7]. Nonetheless, it remains unclear how, and to what extent, sexual dysfunction relates to pelvic reconstructive surgery. Some studies suggest that sexual dysfunction is a common sequela after mesh augmented reconstructive surgery [8,9], others suggest that surgery has no effect [10–12], or even improve sexual function domains [13,14]. Ambiguous results have also been shown for other quality of life domains in relation pelvic organ prolapse surgery.

We have previously reported on the safety and efficacy outcomes and subjective relief of condition specific symptoms after using the Uphold™ Vaginal Support System [15]. In the present study we assessed quality of life and sexual function outcomes following Uphold™ surgery in a prospective cohort of women with apical prolapse and with or without concurrent cystocele.

* Corresponding author at: Helsinki University Hospital, Department of Obstetrics and Gynecology, BOX 140, 00029 HUS, Helsinki, Finland.
E-mail address: paivi.rahkola-soisalo@hus.fi (P. Rahkola-Soisalo).
Materials and methods

We performed a multicenter, prospective, open label, single cohort study throughout 24 clinics in Sweden, Denmark, Norway and Finland. A total of 207 patients with primary or secondary apical prolapse ≥ stage 2 (point C/D), with or without anterior vaginal wall prolapse ≥ or equal to −1 (point Ba ≥−1), according to POP-Q staging [16], underwent surgery using the Uphold™ Lite Vaginal Support System (Boston Scientific). All patients underwent a pre-trial standardized surgical procedure using the Uphold™ Lite system and all gynecologic surgeons participating in the trial had supervised hands-on operating room training before initiation of the study. The surgical procedure has been described elsewhere [17]. Briefly a small incision was used, leaving approximately 2 cm undisturbed at the vaginal apex. The Caplio® Suture Capturing Device was used to connect the mesh to the sacrospinous ligament and suspending the apex. If decided by the operator, anterior vaginal wall prolapse was corrected concomitantly by traditional colporrhaphia anterior, but there was not any stage of prolapse when this was mandatory. The peri- and postoperative morbidity and complications associated with the procedure were reported by Altman et al. [15]. Follow-up visits were performed at two months and one year after surgery. Five women did not attend any follow-up and thus, the final cohort was 202 women.

There were no restrictions on body mass index, menopausal status, or previous surgery. Other pelvic disorders for which surgery was indicated (including stress incontinence, cervix elongation and posterior prolapse), as well as, previous or current pelvic organ cancer, severe rheumatic disease, insulin treated diabetes mellitus, connective tissue disorder, and current systemic steroid treatment were regarded as exclusion criteria’s.

Vaginal topography and quantification of pelvic organ prolapse was assessed at baseline, as well as, after two months and one year postoperatively during a gynecological exam in the lithotomy position using the POP-Q system [16]. Stage 2 or more of the apical compartment was considered an optimal anatomical outcome after surgery.

Quality of life outcomes were assessed using the Pelvic Floor Distress Inventory 20 (PFDI-20), Pelvic Floor Impact Questionnaire- short form 7 (PFIQ-7), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) at baseline and one year follow-up. The main results of PFDI-20 are reported before [15], but these data were included here when analyzing the possible risk factors for subjective operation failure. The PFQ-7 provides a comprehensive condition specific assessment of the effect of pelvic floor distress on quality of life during the last three months. The questionnaire includes seven questions and three scales: Urinary Impact Questionnaire (UIQ-7), Colorectal-Anal Impact Questionnaire (CRAIQ-7), and Pelvic Organ Prolapse Impact Questionnaire (POPQ-7). The scale score is obtained by the mean value of all the answered questions and multiplying them to obtain scale score from 0 (least impact) to 100 (greatest impact). In the summary higher points indicate more distress. The PISQ consists of 12 questions, which measures the impact of pelvic organ prolapse on the patient’s sexual life during the last six months. The responses are scored on a 5-point Likert scale from “never” to “always”. The questionnaire can be divided to three subscales, behavior-emotional, physical, and partner related. Higher points indicate better sexual satisfaction and the maximum score is 48.

Data on the quality of life questionnaires are presented as means ± SD. Comparison between baseline and one-year outcomes were analyzed by the Wilcoxon –Matched-Paired-Signed-Rank test. As possible risk factors for unsuccessful outcomes (i.e. POP-Q stage ≥2 in point C or an adverse effects on quality of life instruments) we evaluated a number of variables in a multivariate logistic regression analysis including: previous hysterectomy, previous pelvic organ prolapse surgery, age ≥65 years, BMI ≥25, multiparity (≥3 deliveries), chronic diseases (cardiovascular diseases, asthma, thyroid dysfunction, non-insulin treated diabetes, fibromyalgia, rheumatism), and concomitant anterior vaginal wall repair. Results from the risk analysis are presented as odds ratios (ORs) with 95% confidence intervals (CIs). A p-value < 0.05 was considered significant for all analyses. All statistics were performed with IBM SPSS Statistics, version 22.

The study was approved by the appropriate research ethics committees in the participating countries and the study was registered at www.clinicaltrials.gov (NCT01823055). The study protocol was vetted by the mesh manufacturing company prior to providing an investigator initiated study grant but the company had no further influence over execution of the study, analyses and interpretation of the data, or drafting the manuscript. Furthermore, the company provided funding for two investigator meetings held before and after completion of the trial.

Results

Baseline characteristics of the patients included in the study are presented in Table 1. In total 88% of the women were postmenopausal (183) and 38% (79 women) had a history of previous hysterectomy. Mean age at surgery was 66.3 (SD ±9.2) years, mean body mass index (BMI) was 25.3 (SD ±4.6) and median parity was 2 (range 0–5).

The PFQ-7 questionnaire was filled adequately by 197 women at baseline, and after one year by 183 women. Of these women 179 filled the questionnaires adequately both at baseline and at one year. One hundred-sixteen (64.8%) women had lower score points one year postoperatively indicating an improved quality of life, 19 (10.6%) women reported no change, and 44 (24.6%) women showed worsening in quality of life. Detailed outcome of PFQ-7 questionnaire is presented in Table 2. Pelvic organ prolapse and urinary symptoms caused equal distress before the operation. The total score points showed an overall improved quality of life at one-year follow-up (p < 0.001) (Table 2). Both pelvic organ prolapse and urinary problems improved significantly after one year (p < 0.001), whereas in the colorectal-anal scale no statistically significant change was detected (Table 2).

Table 1

<table>
<thead>
<tr>
<th>Baseline characteristics and the operation information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age y, mean ± SD (range)</td>
</tr>
<tr>
<td>Weight</td>
</tr>
<tr>
<td>BMI mean ± SD (range)</td>
</tr>
<tr>
<td>Parity median (range)</td>
</tr>
<tr>
<td>Multiparous (≥3 deliveries) N (%)</td>
</tr>
<tr>
<td>Menopause N (%)</td>
</tr>
<tr>
<td>Smokers N (%)</td>
</tr>
<tr>
<td>Somatic diseases N (%)</td>
</tr>
<tr>
<td>No diseases</td>
</tr>
<tr>
<td>Cardiovascular diseases</td>
</tr>
<tr>
<td>Thyroid dysfunction</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Fibromyalgia + rheumatism</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Previous surgeries N (%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
</tr>
<tr>
<td>Subjects with previous pelvic floor surgery</td>
</tr>
<tr>
<td>Operating time min (mean ± SD)</td>
</tr>
<tr>
<td>Bleeding ml, mean ± SD (range)</td>
</tr>
<tr>
<td>Hospital stay days median (range)</td>
</tr>
</tbody>
</table>
Table 2
Pelvic floor impact quality questionnaire results.

<table>
<thead>
<tr>
<th></th>
<th>Preop. N = 197</th>
<th>1 year N = 193</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic organ prolapse impact</td>
<td>49.4 ± 25</td>
<td>36.4 ± 13.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Colorectal-anal impact</td>
<td>39.1 ± 20.4</td>
<td>36.2 ± 11.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Urinary impact</td>
<td>49.7 ± 23.3</td>
<td>40.1 ± 13.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total</td>
<td>138.5 ± 59.8</td>
<td>105.1 ± 42.5</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Means ± SD.

At baseline 95 women and after one year 97 women answered the PISQ-12 questionnaire adequately. Of these 94 women answered completely for both questionnaires. In 62 (66.0%) women total score points reduced postoperatively indicating worsening in sexual function, 10 (10.6%) women reported unchanged situation, and 22 (23.4%) women showed improved sexual function. Overall sexual satisfaction was reduced (p < 0.001) after one-year follow-up (Table 3). In the subscale analyses the score points did not differ in the behavioral-emotive and physical sections before and after surgery. There was, however, a specific decrease in the partner subscale postoperatively (Table 3).

With regard to postoperative dyspareunia in specific (PISQ-12, question 5) a total of 98 women answered the question both pre and postoperatively. Of these 58/98 women (59.2%) had some dyspareunia preoperatively whereas 42 reported (42.9%) dyspareunia postoperatively (p = 0.004). Fifty patients reported no change, 32 patients improved, and in 16 patients dyspareunia worsened. A worsening in dyspareunia was reported by 81.1% of all studied women having an Uphold procedure vs. 8.3% among women having Uphold with concomitant colporrhaphy (p = 0.09). Similarly, 12.5% of women reported a complete resolution of dyspareunia after an isolated Uphold procedure vs. 11.7% among patients having Uphold with concomitant colporrhaphy (p = 0.6).

In Table 4 we present the results for the association between possible predictors and a worsening of condition specific symptoms, quality of life, sexual function and anatomical outcomes. Chronic disease improved the odds of quality of life improvement (OR 0.4, 95% CI; 0.2–0.9) whereas an age ≥65 increased the risk for de novo pelvic organ prolapse (OR 2.5, 95% CI; 1.01–6.2). There were no significant associations between any of the co-variates and sexual dysfunction or anatomical outcomes (Table 4).

In the subscale analyses of both the PFDI-20 (UDI-6) and the PFIQ-7 (UIQ-7) there was increased odds for improved urinary distress in women with BMI ≥25 (OR 0.3, 95% CI; 0.1–0.7, and OR 0.5, 95% CI; 0.2–0.9, respectively). Among women with a history of previous pelvic floor surgery and among women with an isolated Uphold™ (no concurrent anterior colporrhaphy) there was an increased risk that the operation worsened urinary distress (UIQ-7; OR 2.2, 95% CI; 1.1–4.4 and OR 2.3, 95% CI; 1.1–4.9, respectively). Having an isolated Uphold™ operation also increased the risk for prolapse related bother one year after surgery (POP-IQ-7; OR 2.1, 95% CI; 1.01–4.3).

Comment

The total scores indicated that the Uphold™ operation significantly improved quality of life as reflected by lower scores postoperatively for the PFIQ-7. At baseline there was almost as much distress from urinary symptoms as from pelvic organ prolapse, and both these symptoms of pelvic floor dysfunction improved significantly after the operation. These results are comparable with previous studies on the use of mesh in pelvic organ prolapse repair [31,18–20].

Despite the improvement in quality of life, PISQ-12 scores showed an overall worsening in sexual function 1-year postoperatively. The deterioration was mainly attributed to negative effects in the partner related domain whereas the behavioral-emotive and physical domains showed no significant changes. To some extent this concurs with a previous cohort study showing that transvaginal mesh is associated with deteriorating partner related sexual function [8]. Although partner related sexual dysfunction after prolapse surgery is a recurrent finding in studies on pelvic organ prolapse surgery the mechanisms for this finding are poorly understood. It is possible that the PISQ-questionnaire as a tool to describe sexual function, although responsive to change after surgery [21], does not provide a comprehensive and detailed enough evaluation of the complexity involved in sexual function after reconstructive surgery. In-depth studies on sexual dysfunction related to pelvic organ prolapse surgery are scarce. In a mixed quantitative and qualitative study [22], the investigators found that partner avoidance of sexual activity was greater in women after prolapse surgery as compared to incontinence surgery. In contrast, another study [23] showed that sexual function in male partners of women after pelvic organ prolapse surgery was unchanged or even improved. Moreover, it is possible that this worsening is attributable to prolapse surgery itself – regardless of using mesh or not [24]. However, we may conclude that partner related dysfunction after mesh augmented or native tissue prolapse repair may be an important cause of postoperative sexual dysfunction and deserves further attention.

Table 3
Pelvic Organ prolapse/Urinary Incontinence Sexual Questionnaire results.

<table>
<thead>
<tr>
<th></th>
<th>Baseline N = 95</th>
<th>1 year N = 97</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavioral emotive</td>
<td>6.9 ± 3.5</td>
<td>6.8 ± 3.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Physical</td>
<td>4.7 ± 3.0</td>
<td>4.2 ± 2.6</td>
<td>0.07</td>
</tr>
<tr>
<td>Partner</td>
<td>3.6 ± 2.9</td>
<td>1.6 ± 2.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Summary Score</td>
<td>15.2 ± 6.1</td>
<td>12.6 ± 6.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Means ± SD.

Table 4
Odd ratios OR for unsuccessful operation result after one year follow-up (POP-Q < 2 apical compartment, PFDI-20, PFIQ-7, PISQ-12).

<table>
<thead>
<tr>
<th></th>
<th>De novo prolapse</th>
<th>Apical success</th>
<th>PFDI-20</th>
<th>PFIQ-7</th>
<th>PISQ-12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>OR</td>
<td>95% CI</td>
<td>OR</td>
</tr>
<tr>
<td>Previous hysterectomy</td>
<td>1.2</td>
<td>0.5–2.7</td>
<td>0.8</td>
<td>0.2–3.3</td>
<td>0.8</td>
</tr>
<tr>
<td>Previous pelvic floor surgery</td>
<td>0.8</td>
<td>0.4–1.7</td>
<td>1.1</td>
<td>0.3–4.6</td>
<td>2.4</td>
</tr>
<tr>
<td>BMI ≥25</td>
<td>1.3</td>
<td>0.6–2.8</td>
<td>0.8</td>
<td>0.2–3.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Multiparous</td>
<td>1.1</td>
<td>0.5–2.4</td>
<td>0.6</td>
<td>0.2–3.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Age ≥65</td>
<td>2.5</td>
<td>1.01–6.2</td>
<td>0.2</td>
<td>0.2–1.9</td>
<td>3.6</td>
</tr>
<tr>
<td>Chronic disease</td>
<td>0.8</td>
<td>0.4–1.9</td>
<td>0.7</td>
<td>0.1–4.0</td>
<td>3.3</td>
</tr>
<tr>
<td>Isolated Uphold™ operation</td>
<td>0.5</td>
<td>0.2–1.1</td>
<td>0.5</td>
<td>0.1–2.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

* p-values for significant OR.
Postoperative dyspareunia is the area of sexual dysfunction that has received the greatest attention relating to urogynecological surgery. Again findings from previous studies are conflicting and some studies show an increased risk for dyspareunia after surgery whereas others detected no change [8–14]. We found that the number of women with dyspareunia decreased postoperatively, even if almost half of the women who answered the question (42/98) had some dyspareunia one year after the operation. Most of these women presented dyspareunia seldom or sometimes, and only four women had pain often or always. However, it is notable that only 48.5% of women answered the question and thus, it is possible that the true rate of dyspareunia was higher. There was no difference in either worsening or improvement of dyspareunia when comparing women having an isolated Uphold™ procedure compared to those having it in combination with anterior colporraphy. These numbers are comparable with previous study where 8% of women had de novo dyspareunia after Uphold operation [25]. It is possible that the decreased biomaterial load and smaller surface of the mesh when performing an apical suspension procedure such as Uphold™ decreases the risk for postoperative dyspareunia when compared to the large scale transvaginal meshes used to cover defects of the vaginal walls [8,9]. Thus, our data suggest that performing an anterior colporraphy at the time of an Uphold procedure does not add to the risk of postoperative dyspareunia, whereas overall conclusions on sexual function and dyspareunia are restricted.

We evaluated risk factors in subjective and objective outcomes, as well as, for de novo prolapse. Surprisingly, the only significant variable positively associated with an overall improvement in quality of life (PFIQ-7) was co-existent chronic diseases. It is possible that women affected by multiple chronic diseases experience after surgery improvements in prolapse symptoms more clearly than otherwise healthy women with perhaps greater expectations on daily function. Age >65 years was a risk factor for de novo prolapse which likely reflects the association between prolapse and age [26]. In addition, it is possible that among elderly women, with overall poorer tissue quality, the effectiveness of mesh surgery in the affected compartment may promote de novo prolapse in other compartments [27].

Women having an isolated Uphold™ operation reported less improvement in both lower urinary tract and pelvic organ prolapse related distress as compared to women having a concomitant cystocele operation. This is in line with our finding that women without any preoperative cystocele reported at baseline less urinary distress (PFDI-20; p = 0.004). Concomitant cystocele repair may increase the support of the bladder neck providing additional improvement of lower urinary tract symptoms and especially stress urinary incontinence. It is known that isolated traditional cystocele correction relieves preoperative stress urinary incontinence in 27% of the women [28]. Furthermore, the concomitant cystocele repair probably provide better overall support to the anterior compartment than Uphold™ alone resulting in improved symptom relief. In the subscale analyses of both the PFDI-20 and PFIQ-7, a higher degree of satisfaction with regard to lower urinary tract symptoms were found in obese women (BMI ≥25). Since obese women had more distress in the urinary sections preoperatively (PFDI-20: p < 0.001, PFIQ-7: p = 0.06), they likely benefited more from the operation than normal weight women.

The apparent limitation of our study is that approximately half of our patients chose not to reply to the PISQ-12. In addition, our non-randomized study design include potential bias such as doctor-patient relationship, care seeking behavior, and patient/surgeon preferences. As a strength of our study can be regarded the prospective, multicenter and multinational study setting.

In conclusion, use of the Vaginal Uphold™ Support System for apical prolapse repair improve quality of life and no specific risk factors for subjective operation failure could be identified. However, there was an overall worsening in sexual function postoperatively.

Conflict of interest

E. Marcos report no conflict of interest. P. Rahkola-Soisalo has received advisory honoraria from Johnson & Johnson, M. Rudnicki has received advisory honoraria from Pfizer, D’Altmann has received speaking and advisory honoraria from Gedeon Richter, Pfizer, Astellas, Invent Medic and Gynecare. C. Falconer has received speaking and advisory honoraria from Boston Scientific and Johnson & Johnson. T. S. Mikkola has received speaking honoraria from Astellas and Contura.

Acknowledgements

The study was supported by an investigator initiated grant from Boston Scientific, grants from the Finnish Medical Foundation, and the Swedish Scientific Council.

References


